BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8349151)

  • 1. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
    Goff BA; Rice LW; Fleischhacker D; Muntz HG; Falkenberry SS; Nikrui N; Fuller AF
    Gynecol Oncol; 1993 Jul; 50(1):105-9. PubMed ID: 8349151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.
    Leitao MM; Sonoda Y; Brennan MF; Barakat RR; Chi DS
    Gynecol Oncol; 2003 Oct; 91(1):209-12. PubMed ID: 14529683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
    Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
    Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
    Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
    Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatment in adult uterine sarcomas.
    Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
    Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China.
    Li D; Yin N; Du G; Wang S; Xiao Z; Chen J; Chen W
    Int J Biol Sci; 2020; 16(3):388-395. PubMed ID: 32015676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
    Machida H; Nathenson MJ; Takiuchi T; Adams CL; Garcia-Sayre J; Matsuo K
    Gynecol Oncol; 2017 Mar; 144(3):524-530. PubMed ID: 28109626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcome in women with uterine sarcoma.
    Denschlag D; Masoud I; Stanimir G; Gilbert L
    Eur J Surg Oncol; 2007 Feb; 33(1):91-5. PubMed ID: 17174517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine sarcoma: the Hacettepe hospital experience of 88 consecutive patients.
    Ayhan A; Tuncer ZS; Tanir M; Yüce K; Ayhan A
    Eur J Gynaecol Oncol; 1997; 18(2):146-8. PubMed ID: 9105869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
    Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
    Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
    Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
    Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
    Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
    Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
    Lax SF; Tamussino KF; Lang PF
    Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study.
    Major FJ; Blessing JA; Silverberg SG; Morrow CP; Creasman WT; Currie JL; Yordan E; Brady MF
    Cancer; 1993 Feb; 71(4 Suppl):1702-9. PubMed ID: 8381710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine sarcoma in the south of Israel: study of 36 cases.
    Piura B; Rabinovich A; Yanai-Inbar I; Cohen Y; Glezerman M
    J Surg Oncol; 1997 Jan; 64(1):55-62. PubMed ID: 9040802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
    Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
    J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation.
    Yilmaz A; Rush DS; Soslow RA
    Am J Surg Pathol; 2002 Sep; 26(9):1142-50. PubMed ID: 12218570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD146 as an adverse prognostic factor in uterine sarcoma.
    Zhou Y; Huang H; Yuan LJ; Xiong Y; Huang X; Lin JX; Zheng M
    Eur J Med Res; 2015 Aug; 20(1):67. PubMed ID: 26293576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
    Wang F; Dai X; Chen H; Hu X; Wang Y
    BMC Cancer; 2022 Oct; 22(1):1050. PubMed ID: 36207687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.